arrow
C

Christian M. Capitini

university of wisconsin
H指数:29
被引数:2,584

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells

使用抗uPAR嵌合抗原受体指导T细胞产品内部的同胞杀伤,以驱动强效治疗性细胞的产生

2026-09-020
PRE
PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis

PRMT5抑制增强B细胞淋巴瘤细胞对铁死亡的敏感性

Leukemia
IF13.4
2026-04-170
OAAI
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer

CAR T细胞治疗在儿童、青少年和青年癌症患者中的典型作用

2026-01-230
PRE
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity

一种评估核心针活检中免疫治疗反应并解决肿瘤异质性挑战的活肿瘤片段平台

2026-01-030
OAAI
Extracellular vesicles from mesenchymal stromal cells primed with synthetic toll-like receptor 4 agonists treat hematopoietic acute radiation syndrome

间充质基质细胞经合成 toll 样受体 4 激动剂预处理后分泌的细胞外囊泡可治疗造血急性放射综合征

2026-01-010
PRE
Combined innate immune cell therapy; tumor-specific antibody; and radiation prompt antitumor response in pancreatic cancer models

联合固有免疫细胞疗法;肿瘤特异性抗体;以及放射诱导产生抗肿瘤反应在胰腺癌模型中

2025-12-050
OA
CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma

CD155阻断增强了异基因自然杀伤细胞介导的对骨肉瘤的抗肿瘤反应

2025-04-150
OA
Autofluorescence lifetime imaging classifies human B and NK cell activation state

自体荧光寿命成像分类人B细胞和NK细胞活化状态

2025-04-040
OA
SITC strategic vision: prevention, premalignant immunity, host and environmental factors

SITC战略愿景:预防、癌前免疫、宿主和环境因素

2025-03-280
OA
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

癌症免疫治疗学会(SITC)关于免疫治疗临床方案关键生物标志物的共识声明

2025-03-071
OA
Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT

利用Cas9-CLIPT实现高效的非病毒方式将大型转基因整合到人T细胞中

2025-02-010
OAAI
Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells

将嵌合抗原受体无病毒CRISPR敲入KLRC1可生成强效GD2特异性自然杀伤细胞

2025-01-010
PRE
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas

tisagenlecleucel在复发或难治性b细胞淋巴瘤的儿童和年轻人中的实际应用

2024-08-020
OAAI
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

靶向小胶质细胞中tgf β 活化激酶-1活化可降低CAR T免疫效应细胞相关神经毒性综合征

2024-05-133
PRE